PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27743887-8 2017 Our patient shows that folinic acid therapy can ameliorate the clinical symptoms, white matter disturbances, cortical insults, and peripheral neuropathy of cerebral folate deficiency caused by FOLR1 mutation. Leucovorin 23-35 folate receptor alpha Homo sapiens 193-198 34442354-8 2021 Autoantibodies against folate receptor alpha (FRalpha) are present in about 70% of the children with a diagnosis of ASD, and a significant number of these children respond to oral folinic acid with overall improvements in speech, language and social interaction. Leucovorin 180-192 folate receptor alpha Homo sapiens 23-44 34008900-8 2021 It is crucial to recognize FOLR1 signs and establish an early clinical and molecular diagnosis in order to provide timely folinic acid treatment and improve outcome. Leucovorin 122-134 folate receptor alpha Homo sapiens 27-32 27363740-7 2016 The patient with FOLR1 gene mutation had extremely low CSF 5MTHF and total folate, though these values normalized after folinic acid supplementation. Leucovorin 120-132 folate receptor alpha Homo sapiens 17-22 28155935-0 2017 Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin. Leucovorin 93-103 folate receptor alpha Homo sapiens 0-22 28155935-2 2017 Here, we have investigated the concentration- and ligand-dependent aggregation of folate binding protein (FBP), focusing in particular on folic acid, an important vitamin and targeting agent; methotrexate, an antifolate drug used to treat cancer and rheumatoid arthritis; and leucovorin which is used to decrease methotrexate toxicity. Leucovorin 276-286 folate receptor alpha Homo sapiens 106-109 27328863-0 2016 Neurological improvement following intravenous high-dose folinic acid for cerebral folate transporter deficiency caused by FOLR-1 mutation. Leucovorin 57-69 folate receptor alpha Homo sapiens 123-129 27328863-12 2016 CONCLUSIONS: This report illustrates that cerebral folate transporter deficiency caused by FOLR-1 mutations is a treatable condition and can potentially be cured by folinic acid treatment. Leucovorin 165-177 folate receptor alpha Homo sapiens 91-97 25841994-8 2015 The identification of this FRalpha-STAT3 signal transduction pathway activated by folic and folinic acid contributes to the understanding of the involvement of folic acid in preventing neural tube defects as well as in tumour growth. Leucovorin 92-104 folate receptor alpha Homo sapiens 27-40